Ouroboros Medicines is a biotechnology company specializes in immunology.
Ouro Medicines has raised $120.0M in total funding. The most recent round was Series A. The last funding was announced in January 2025.
Ouro Medicines's investors include TPG, Norwest, New Enterprise Associates, Boyu Capital, Monograph Capital.
Ouro Medicines is headquartered in San Francisco, United States.
Ouroboros Medicines is a biotechnology company specializes in immunology.
Ouro Medicines is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ouro Medicines — Funding & Investors." VCBacked, January 10, 2025, https://www.vcbacked.co/company/ouro-medicines. Accessed September 1, 2026.
VCBacked. (2025). Ouro Medicines — Funding & Investors. Retrieved September 1, 2026, from https://www.vcbacked.co/company/ouro-medicines
{{cite web |title=Ouro Medicines — Funding & Investors |url=https://www.vcbacked.co/company/ouro-medicines |website=VCBacked |access-date=September 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated